Yaman Lu

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease”.

Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease

EBioMedicine(2021)10.1016/j.ebiom.2021.103380

N/A

1.2DataRank · unranked

58 citations

Krista L. Namminga, Yaman Lu, Aaron Schwab, Mackenzie J. Thurston, Mai Mohamed Abdelmoaty +7 more

An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

Translational Neurodegeneration(2023)10.1186/s40035-023-00361-1

N/A

0.759DataRank · unranked

33 citations

Mai Mohamed Abdelmoaty, Krista L. Namminga, Yaman Lu, Helen Obaro, Pamela M. Santamaria +3 more

Development of an extended half-life GM-CSF fusion protein for Parkinson's disease

Journal of Controlled Release(2022)10.1016/j.jconrel.2022.06.024

N/A

0DataRank · unranked

38 citations

Katherine E. Olson, Yaman Lu, Mai Mohamed Abdelmoaty, Krista L. Namminga, Milica Marković +4 more

Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease

NeuroImmune Pharmacology and Therapeutics(2022)10.1515/nipt-2022-0001

N/A

0DataRank · unranked

18 citations

Pravin Yeapuri, Krista L. Namminga, Yaman Lu, Maamoon Saleh, Katherine E. Olson +3 more

A multiyear follow-on study examining safety, immunity, and clinical outcomesfor sargramostim therapy in Parkinson’s disease

Research Square(2022)10.21203/rs.3.rs-1957469/v1

N/A

0DataRank · unranked

0 citations

Katherine E. Olson, Krista L. Namminga, Yaman Lu, Mai Mostafa, Helen Obaro +3 more

Amyloid-β specific regulatory T cells attenuate Alzheimer’s disease pathobiology in APP/PS1 mice

Molecular Neurodegeneration(2023)10.1186/s13024-023-00692-7

N/A

0DataRank · unranked

76 citations

Jatin Machhi, Yaman Lu, Mai Mohamed Abdelmoaty, Rana Kadry, Milankumar Patel +8 more

Immune senescence in aged APP/PS1 mice

NeuroImmune Pharmacology and Therapeutics(2023)10.1515/nipt-2023-0015

N/A

0DataRank · unranked

10 citations

Pravin Yeapuri, Jatin Machhi, Yaman Lu, Krista L. Namminga, Rana Kadry +5 more

Amyloid precursor protein and presenilin‐1 knock‐in immunodeficient mice exhibit intraneuronal Aβ pathology, microgliosis, and extensive neuronal loss

Alzheimer s & Dementia(2025)10.1002/alz.70084

N/A

0DataRank · unranked

12 citations

Jatin Machhi, Emma G. Foster, Rana Kadry, Shaurav Bhattarai, Yaman Lu +9 more

Neuroprotective Activities of Long-Acting Granulocyte–Macrophage Colony-Stimulating Factor (mPDM608) in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Intoxicated Mice

Neurotherapeutics(2020)10.1007/s13311-020-00877-8

N/A

0DataRank · unranked

38 citations

Krista L. Namminga, Aaron Schwab, Mackenzie J. Thurston, Yaman Lu, Ashley Woods +7 more

HIV-1 infection facilitates Alzheimer’s disease pathology in humanized APP knock-in immunodeficient mice

NeuroImmune Pharmacology and Therapeutics(2025)10.1515/nipt-2024-0018

N/A

0DataRank · unranked

5 citations

Rana Kadry, Pravin Yeapuri, Yaman Lu, Emma G. Foster, Chen Zhang +6 more

CD4+ effector T cells accelerate Alzheimer’s disease in mice

Journal of Neuroinflammation(2021)10.1186/s12974-021-02308-7

N/A

0DataRank · unranked

154 citations

Pravin Yeapuri, Yaman Lu, Emma G. Foster, Rupesh V. Chikhale, Jonathan Herskovitz +15 more